Author(s): Abraham RT
Abstract Share this page
Abstract Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion. Copyright © 2012 Elsevier Inc. All rights reserved.
This article was published in Cancer Cell
and referenced in Autism-Open Access